BioSpace News Archive

Tessa Therapeutics Ltd. announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.

West Pharmaceutical Services, Inc. announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022.

OneOncology, the national platform for independent oncology practices, appointed Thomas Stricker, MD as Medical Director for Precision Medicine.

The subscription period begins in Spago Nanomedical AB’s rights issue of shares of up to SEK 61.8 million, as resolved by the Board with the support of the authorization received at the Annual General Meeting on May 18, 2022.

TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.

Endo International plc announced that its subsidiary Endo Ventures Limited has executed an agreement with Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.

ImmunoGen Inc. announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, utilizing ImmunoGen’s proprietary linker-payload technology directed to novel targets identified via OBT’s proprietary OGAP® discovery platform.

Wilmington, Delaware, United States: The global collagen market was valued at US$ 4.7 Bn in 2020.

Patients suffering from burns are increasingly demanding procedures to improve their physical appearance.